New publication on rapid AST platform
The fluidic chip developed by Gradientech and Uppsala University can determine bacterial susceptibility to multiple antibiotics within 2-4 hours. The technology has the potential to allow for faster initiation of targeted treatment for sepsis patients.
The results serve as a proof-of-concept for the commercial QuickMIC® AST system that Gradientech is currently developing.
Next-generation antimicrobial susceptibility testingTake a look at our E-book